Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

1. Founder’s Vision

Founder’s vision has evolved across three distinct phases of LPBI Group’s development:

• 1.0 LPBI Group (2012–2021): Established as an e-Scientific Publisher with a focus on high-quality curation of peer-reviewed scientific findings.
• 2.0 LPBI Group (2022–2025): Expanded into Medical Text Analysis using Artificial Intelligence, Machine Learning, and NLP. This phase included pilot studies and the publication of two books presenting the results of AI-driven medical text analysis.
• 2026 & Beyond: Transition to the development of a comprehensive Tool Factory for Multimodal Foundation Models in Healthcare — advancing domain-aware AI in Health through structured methodologies and proprietary data assets.

Since founding LPBI Group in 2012, the core competence has been the clinical interpretation of scientific findings by domain-knowledge experts, combined with systematic curation of peer-reviewed literature. Over 14 years, this discipline produced a unique and defensible portfolio of assets designed to support the next generation of AI systems in healthcare.

The vision since the emergence of the transformer and GPT era (2022–2023) has been to build the highest-quality, proprietary multimodal training data and methodologies capable of transforming artificial intelligence in healthcare from aspiration into reliable, production-grade capability.

Today, LPBI Group has created a differentiated and integrated ecosystem consisting of:

• A 9 GB private multimodal corpus — one of the largest expert-curated trainable datasets in Life Sciences, Pharmaceuticals, Medicine, and Healthcare, developed entirely through the work of advanced-degree professionals.
• The 17-part Composition of Methods (COM) Tool Factory, a proprietary framework that interconnects all assets into causally structured, trainable intelligence. This includes AJAUS (COM Part 14) for governed autonomous orchestration and the Rosetta Stone Ontology (COM Part 15) for clinical mechanism-of-action reasoning.
• 13 Hidden Gems functioning as ready-made Small Language Models (SLMs) across therapeutic areas prioritized by industry (Oncology, Immunology, CNS/Neurology, Cardiovascular, Infectious Disease, Rare Diseases, and others).
• Additional structured datasets in Portals and “Articles of Note” collections in key medical subspecialties.

This portfolio was intentionally designed as a defensible moat to enable frontier models to achieve leadership in domain-aware AI in Health across four core domains: Pharmaceutical/BioPharma, Medical/Diagnosis & Therapeutics, Life Sciences/Genomics, and BioMed/Biotech/Medtech.

The ultimate objective is the Transfer of Ownership of this complete IP ecosystem — the multimodal corpus, the full COM Tool Factory, and the associated domain expertise — to a strategic partner positioned to scale its impact. By doing so, LPBI Group’s curated intelligence and methodologies can be deployed at full capacity to accelerate breakthroughs in medicine and generate lasting value.

This Master Plan represents both the culmination of 14 years of disciplined work and the beginning of a new chapter focused on strategic partnership and large-scale application.

Inventiveness & Integrity: Building a New Factory of Expert-Guided Trainable Databases as the Alternative to Synthetic Generation

Founder’s Vision

From the beginning, LPBI Group has treated knowledge architecture as an act of creation rather than compilation. We do not simply syndicate or repackage existing data vaults. We create new trainable data.

When a new electronic Table of Contents is designed for an e-Book, a previously non-existent structure of knowledge is brought into being. When the velocity of AI information surged after 2023, we pivoted to medical text analysis powered by machine learning. When the explosion of new AI tools became impossible to ignore, we pivoted once more — launching three new trainable databases that did not previously exist:

• The continuous corpus of AI technologies as articulated by KOL Alex Wissner-Gross
• A tightly curated selection of AI-in-Life-Sciences insights from KOL Demis Hassabis
• The Founder’s Radar Screens tracking competitive dynamics across Agentic-AI software, compute hardware, AI harnesses in drug discovery, and strategic partnerships between AI-native companies and BioPharma

These living databases sit on top of our original 9 GB multimodal archive. They are shaped by continuous expert judgment and filtered exclusively through relevance to LPBI’s mission and to the further development of the Composition of Methods (COM) Suite.

This inventiveness is inseparable from integrity. We claim ownership only of what we actually own: high-provenance multimodal data and a complete structured methodology layer. We do not claim compute infrastructure. We do not claim causal-reasoning algorithms. We do not inflate the stack.

In a market where overstatement is common, precise ownership claims are both ethically required and strategically protective. Sophisticated partners will eventually detect any exaggeration. By stating boundaries clearly, we protect trust and keep the focus on the real scarcity we offer.

Expert-guided trainable databases of this kind are not a substitute for synthetic data — they are a superior alternative. They carry human judgment, provenance, and mission alignment that purely synthetic generation cannot replicate.

This is the vision that continues to guide LPBI Group.